130 related articles for article (PubMed ID: 32750756)
21. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid Cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract][Full Text] [Related]
22. AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Kondakova IV; Volkov MY; Dobrodeev AY; Boronkina AI
Bull Exp Biol Med; 2020 Nov; 170(1):75-78. PubMed ID: 33231797
[TBL] [Abstract][Full Text] [Related]
23. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
24. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
25. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited.
Kebebew E; Treseler PA; Ituarte PH; Clark OH
World J Surg; 2001 May; 25(5):632-7. PubMed ID: 11369991
[TBL] [Abstract][Full Text] [Related]
26. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
27. [Clinicopathological significance of Golgi phosphoprotein 3 expression in papillary thyroid carcinoma].
Huang DH; Jin L; Xie WW; Lin Q; Chen X
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2831-2835. PubMed ID: 31550811
[No Abstract] [Full Text] [Related]
28. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; DeSouza P; Yang T; Niles N
Thyroid; 2018 Mar; 28(3):349-361. PubMed ID: 29455638
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive screening for PD-L1 expression in thyroid cancer.
Ahn S; Kim TH; Kim SW; Ki CS; Jang HW; Kim JS; Kim JH; Choe JH; Shin JH; Hahn SY; Oh YL; Chung JH
Endocr Relat Cancer; 2017 Feb; 24(2):97-106. PubMed ID: 28093480
[TBL] [Abstract][Full Text] [Related]
31. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
32. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
33. A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
Naito M; Tamiya A; Takeda M; Taniguchi Y; Saijo N; Naoki Y; Okishio K; Yoon H; Kasai T; Matsumura A; Atagi S
Intern Med; 2019 Apr; 58(7):921-927. PubMed ID: 30568128
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.
An HJ; Ko GH; Lee JH; Lee JS; Kim DC; Yang JW; Kim MH; Kim JP; Jung EJ; Song DH
J Pathol Transl Med; 2018 Jan; 52(1):9-13. PubMed ID: 28994272
[TBL] [Abstract][Full Text] [Related]
35. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
[TBL] [Abstract][Full Text] [Related]
36.
Vos L; Dietrich J; Strieth S; Bootz F; Dietrich D; Franzen A
Immunotherapy; 2020 Aug; 12(12):903-920. PubMed ID: 32684057
[No Abstract] [Full Text] [Related]
37. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
38. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
39. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
40. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
